About Event
Welcome to the 2nd Annual Non-Viral RNA Delivery Systems Summit
With over 200 ongoing non-viral delivery-based RNA clinical trials and the expectation of further growth in the coming years, the need to overcome the primary hurdle of delivering RNA drugs is escalating.
The 2nd Annual Non-Viral RNA Delivery Systems Summit took place in Boston this November, and gathered industry heavyweights such as AstraZeneca, Eli Lilly, and Novartis along with exciting new players such as Transcode Therapeutics, Tiba Biotech, Nosis Biosciences, and 20Med Therapeutics to bring you the latest cutting edge non-viral delivery systems for your RNA therapeutics.
This exclusive event provided a platform for networking with a highly senior and technical crowd composed of CXOs and VPs, Directors, and Heads of Drug Formulation, Process and Analytical Development, and Delivery Technologies.
Peers United to:
Who Did You Meet?

What Your Peers Had to Say:
“The ample opportunities given to network with leaders and innovators in the field of nucleic acid delivery were invaluable and the highlight of the summit.”
Senior Scientist, Arcturus Therapeutics